Agios Reports Strong Q1 Product Revenue Growth, Advances Sickle Cell sNDA, Despite Wider Net Loss

summarizeSummary

Agios Pharmaceuticals reported a wider net loss in Q1 2026 but achieved significant product revenue growth and advanced its pipeline, including plans for an accelerated sNDA submission for sickle cell disease.

check_boxKey Events · Earnings and Guidance · AGIO

• Q1 2026 Financial Results

  Reported a net loss of $99.1 million, compared to a net loss of $89.3 million in Q1 2025. Net loss per share was $(1.69).

• Strong Product Revenue Growth

  Worldwide net revenues for mitapivat (PYRUKYND® and AQVESME™) more than doubled to $20.7 million in Q1 2026, up from $8.7 million in Q1 2025.

• Successful AQVESME Launch

  The initial U.S. commercial launch of AQVESME in thalassemia generated 242 prescriptions as of March 31, 2026.

• Accelerated Approval Pathway for Sickle Cell Disease

  Agios plans to submit a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease under the U.S. accelerated approval pathway in the second quarter of 2026.

auto_awesomeAnalysis · AGIO · Life Sciences

Agios Pharmaceuticals reported a mixed first quarter, with a wider net loss of $99.1 million and a net loss per share of $(1.69). However, this was significantly offset by strong operational progress. Worldwide net revenues for its mitapivat products more than doubled year-over-year, driven by a successful U.S. launch of AQVESME in thalassemia. The company also announced plans to submit a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease under the accelerated approval pathway in the second quarter, which could significantly expedite market access for this indication. With $1.0 billion in cash, the company maintains a strong financial position to fund its pipeline and commercialization efforts, indicating a focus on growth and long-term value despite current losses.